0001209191-20-065591.txt : 20201230
0001209191-20-065591.hdr.sgml : 20201230
20201230195140
ACCESSION NUMBER: 0001209191-20-065591
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201224
FILED AS OF DATE: 20201230
DATE AS OF CHANGE: 20201230
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ramelmeier Rolf Andrew
CENTRAL INDEX KEY: 0001789340
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 201427152
MAIL ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-24
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001789340
Ramelmeier Rolf Andrew
C/O SANGAMO THERAPEUTICS, INC.
7000 MARINA BLVD
BRISBANE
CA
94005
0
1
0
0
EVP, Technical Operations
Common Stock
2020-12-24
2020-12-24
4
S
0
3331
18.13
D
68442
D
Includes: (a) 2,000 shares acquired by the Reporting Person on April 30, 2020; and (b) 645 shares acquired by the Reporting Person on October 30, 2020 under the Issuer's 2010 Employee Stock Purchase Plan, as amended.
Also included in this total are: (a) 8,333 shares from the Reporting Person's February 25, 2019 restricted stock unit (RSU) grant that will vest in two remaining annual installments on February 25, 2021 and February 25, 2022, resulting in such RSU grant being vested in full on the third (3rd) anniversary of the grant date; and (b) 55,000 shares from the Reporting Person's February 25, 2020 RSU grant that will vest in three annual installments on February 25, 2021, February 25, 2022 and February 25, 2023, resulting in such RSU grant being vested in full on the third (3rd) anniversary of the grant date.
All such RSUs are granted pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended") and vested or will vest with respect to 1/3rd of the shares in each respective RSU grant in three equal annual installments over the three-year period measured from the dates of grant, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended.
/s/ Matthew Colvin, Attorney-in-Fact for Andy Ramelmeier
2020-12-30